Jazz Pharmaceuticals (JAZZ) Stock Rating Reaffirmed by Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a report published on Tuesday morning. The firm currently has a $201.00 price objective on the specialty pharmaceutical company’s stock.

“: We reiterate our Overweight rating and we are lowering our PT by $2 to $201 for JAZZ stock. We continue to believe management has positioned the company well for a solid financial performance in a post-Xyrem” world through innovation and diversification. We believe NT stock performance will be driven by potential FDA approval of solriamfetol and JZP-258 data in narcolepsy.”,” the firm’s analyst wrote.

Other equities analysts have also issued research reports about the stock. Citigroup upped their target price on shares of Jazz Pharmaceuticals from $162.00 to $205.00 and gave the stock a buy rating in a research report on Tuesday, July 10th. Leerink Swann upped their target price on shares of Jazz Pharmaceuticals from $200.00 to $210.00 and gave the stock an outperform rating in a research report on Friday, August 17th. Evercore ISI restated a buy rating on shares of Jazz Pharmaceuticals in a research report on Friday, July 13th. Piper Jaffray Companies restated a buy rating and set a $213.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, August 8th. Finally, Seaport Global Securities restated a buy rating and set a $207.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, August 9th. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating and fourteen have issued a buy rating to the company’s stock. Jazz Pharmaceuticals currently has an average rating of Buy and an average target price of $191.94.

Shares of JAZZ traded up $3.38 during mid-day trading on Tuesday, reaching $145.57. The stock had a trading volume of 1,051,546 shares, compared to its average volume of 631,079. The firm has a market cap of $8.47 billion, a P/E ratio of 15.23, a PEG ratio of 0.76 and a beta of 1.06. Jazz Pharmaceuticals has a 12 month low of $130.15 and a 12 month high of $184.00. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.29 and a quick ratio of 3.62.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $3.58 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.32 by $0.26. The business had revenue of $469.37 million during the quarter, compared to analyst estimates of $482.64 million. Jazz Pharmaceuticals had a net margin of 28.09% and a return on equity of 24.92%. The company’s revenue was up 14.0% on a year-over-year basis. During the same period in the prior year, the business posted $3.22 earnings per share. Equities analysts anticipate that Jazz Pharmaceuticals will post 11.71 earnings per share for the current year.

In related news, Director Patrick G. Enright sold 10,130 shares of the company’s stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $168.76, for a total transaction of $1,709,538.80. Following the sale, the director now owns 19,884 shares of the company’s stock, valued at $3,355,623.84. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Bruce C. Cozadd sold 1,300 shares of the company’s stock in a transaction on Thursday, November 1st. The shares were sold at an average price of $159.45, for a total transaction of $207,285.00. Following the sale, the chief executive officer now directly owns 278,615 shares in the company, valued at approximately $44,425,161.75. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 16,730 shares of company stock worth $2,796,532. 3.90% of the stock is owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. DekaBank Deutsche Girozentrale raised its stake in Jazz Pharmaceuticals by 3.4% during the third quarter. DekaBank Deutsche Girozentrale now owns 26,607 shares of the specialty pharmaceutical company’s stock valued at $4,607,000 after purchasing an additional 884 shares in the last quarter. BlackRock Inc. raised its stake in Jazz Pharmaceuticals by 2.7% during the third quarter. BlackRock Inc. now owns 4,490,714 shares of the specialty pharmaceutical company’s stock valued at $755,024,000 after purchasing an additional 118,634 shares in the last quarter. Martingale Asset Management L P raised its stake in Jazz Pharmaceuticals by 10,786.8% during the third quarter. Martingale Asset Management L P now owns 174,516 shares of the specialty pharmaceutical company’s stock valued at $29,342,000 after purchasing an additional 172,913 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Jazz Pharmaceuticals by 14.0% during the third quarter. Bank of New York Mellon Corp now owns 1,690,385 shares of the specialty pharmaceutical company’s stock valued at $284,205,000 after purchasing an additional 207,954 shares in the last quarter. Finally, AXA raised its stake in Jazz Pharmaceuticals by 1.1% during the third quarter. AXA now owns 152,029 shares of the specialty pharmaceutical company’s stock valued at $25,560,000 after purchasing an additional 1,669 shares in the last quarter. 92.95% of the stock is currently owned by institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Read More: How Do You Calculate Return on Investment (ROI)?

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply